NASDAQ:NTRANatera Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Natera Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.92 -2.27 (-4.61 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$46.82Now: $46.92▼$49.9050-Day Range$40.54MA: $44.89▼$49.8652-Week Range$16.87Now: $46.92▼$50.57Volume602,600 shsAverage Volume936,280 shsMarket Capitalization$3.69 billionP/E RatioN/ADividend YieldN/ABeta1.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.00, Natera has a potential upside of 0.2% from its current price of $45.89.Amount of Analyst CoverageNatera has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesNatera has received 362 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNatera has received 314 “underperform” votes. (Add your “underperform” vote.)Community SentimentNatera has received 53.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote “Outperform” if you believe NTRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,256,439.00 in company stock.Percentage Held by InsidersOnly 9.29% of the stock of Natera is held by insiders.Percentage Held by Institutions93.87% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.14) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -26.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -26.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 12.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA Previous Symbol CUSIPN/A CIK1604821 Webwww.natera.com Phone650-249-9090Debt Debt-to-Equity Ratio0.38 Current Ratio2.81 Quick Ratio2.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$302.33 million Price / Sales12.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book13.07Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-124,830,000.00 Net Margins-38.28% Return on Equity-78.56% Return on Assets-29.51%Miscellaneous Employees1,039 Outstanding Shares78,725,000Market Cap$3.69 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:NTRA Rates by TradingView Receive NTRA News and Ratings via Email Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter. Natera (NASDAQ:NTRA) Frequently Asked Questions How has Natera's stock been impacted by COVID-19 (Coronavirus)? Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTRA shares have increased by 47.9% and is now trading at $45.89. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Natera? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Natera. When is Natera's next earnings date? Natera is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Natera. How were Natera's earnings last quarter? Natera Inc (NASDAQ:NTRA) announced its earnings results on Wednesday, May, 6th. The medical research company reported ($0.45) EPS for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.12. The medical research company earned $94.01 million during the quarter, compared to analysts' expectations of $85.02 million. Natera had a negative net margin of 38.28% and a negative return on equity of 78.56%. The firm's revenue for the quarter was up 40.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.54) EPS. View Natera's earnings history. What price target have analysts set for NTRA? 8 brokers have issued 12 month target prices for Natera's stock. Their forecasts range from $36.00 to $63.00. On average, they anticipate Natera's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View analysts' price targets for Natera. Has Natera been receiving favorable news coverage? Media coverage about NTRA stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natera earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Natera. Who are some of Natera's key competitors? Some companies that are related to Natera include Guardant Health (GH), InVitae (NVTA), ELEKTA AB/ADR (EKTAY), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC) and Celcuity (CELC). View all competitors. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). Who are Natera's key executives? Natera's management team includes the following people: Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)Mr. Steve Chapman, CEO, Pres & Director (Age 40)Mr. Michael Brophy, Chief Financial Officer (Age 39)Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)Mr. Robert A. Schueren, Chief Operating Officer (Age 57) When did Natera IPO? (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." Who are Natera's major shareholders? Natera's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%). Company insiders that own Natera stock include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View institutional ownership trends for Natera. Which institutional investors are buying Natera stock? NTRA stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Natera. How do I buy shares of Natera? Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $45.89. How big of a company is Natera? Natera has a market capitalization of $3.61 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe. What is Natera's official website? The official website for Natera is www.natera.com. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
